LABS Stock Overview
A pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MediPharm Labs Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.07 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.06 |
| Beta | 0.92 |
| 11 Month Change | -12.50% |
| 3 Month Change | 7.69% |
| 1 Year Change | 7.69% |
| 33 Year Change | -69.57% |
| 5 Year Change | -98.18% |
| Change since IPO | -96.82% |
Recent News & Updates
Recent updates
MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares
Oct 11
MediPharm Labs (TSE:LABS) Is Using Debt Safely
May 29Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?
Sep 06MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 17Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook
Aug 20Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates
May 21Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade
Apr 06Is MediPharm Labs (TSE:LABS) Using Too Much Debt?
Mar 07Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Aug 18Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates
May 23Shareholder Returns
| LABS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -12.5% | -2.4% | 0.4% |
| 1Y | 7.7% | -22.8% | 21.4% |
Return vs Industry: LABS exceeded the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: LABS underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| LABS volatility | |
|---|---|
| LABS Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: LABS has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: LABS's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 166 | David Pidduck | www.medipharmlabs.com |
MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
MediPharm Labs Corp. Fundamentals Summary
| LABS fundamental statistics | |
|---|---|
| Market cap | CA$28.78m |
| Earnings (TTM) | -CA$11.75m |
| Revenue (TTM) | CA$39.05m |
0.7x
P/S Ratio-2.4x
P/E RatioIs LABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABS income statement (TTM) | |
|---|---|
| Revenue | CA$39.05m |
| Cost of Revenue | CA$25.34m |
| Gross Profit | CA$13.71m |
| Other Expenses | CA$25.46m |
| Earnings | -CA$11.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 35.11% |
| Net Profit Margin | -30.10% |
| Debt/Equity Ratio | 1.5% |
How did LABS perform over the long term?
See historical performance and comparison